Recludix Pharma to Participate in Two Investor Conferences in March
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that members of Recludix’s management will host meetings at two investor conferences in March.
- TD Cowen 44th Annual Health Care Conference in Boston, MA on Wednesday, March 6, 2024
- Leerink Partners Global Biopharma Conference in Miami, FL on Tuesday, March 12, 2024
About Recludix
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders and founding scientific team members of Seagen and Blueprint Medicines. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on STAT (signal transducer and activator of transcription) proteins where abnormal activation is found in inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, and inflammatory bowel disease, as well as numerous cancer types, such as multiple leukemias and lymphomas. The company has a strategic partnership with Sanofi for the development and commercialization of a STAT6 inhibitor. Recludix is also advancing STAT3 inhibitors for Th17-mediated I&I diseases and oncology indications, as well as additional programs. For more information, please visit the company’s website at https://recludixpharma.com.
Recludix Contacts:
Alexandra Santos
[email protected]
Aljanae Reynolds
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Statement: EdgeMode confirms that the current review process with BlackBerry AIF and BLACK AI Group will be extended for up to six months
- Terra Balcanica Spin Off Terra North Resources Identifies Radiometric Anomalies over Charlot-Neely Lake in Saskatchewan
- Edible Garden Launches First-to-Market USDA Organic CEA-Grown Basil at Wakefern/ShopRite
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share